Disease-modifying therapies for MS exceed $1 million per QALYCost-utilityGlatiramer-acetate, therapeutic useInterferon-beta-1a, therapeutic useInterferon-beta-1b, therapeutic useMultiple-sclerosis, treatmentThe article focuses on an analysis of the effects and costs of disease-modifying therapies (DMTs)...
例如,在神经免疫学领域,自1993年美国食品药品监督管理局批准首个治疗多发性硬化(multiple sclerosis,MS)的DMT(disease-modifying therapies)药物β-干扰素以来,已经30年过去了,这可能是临床医学领域最早以DMT命名的药物。然而,DMT一词的中文译文含义迄...
(2003) Dise- ase-modifying therapies for multiple sclerosis. Curr Treat Opt in Neurol, 5(1):35-54.John R. Corboy, Douglas S. Goodin, Elliot M. Frohman. (2003) Disease-modifying therapies for multiple sclerosis. Current Treatment Options in Neurology 5 , 35-54 /...
Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year ...
Continuous assessment of infectious risks before, during and after disease-modifying therapy for MS, especially when using intravenous drugs, has increasing clinical relevance Experience with the recently approved oral MS disease-modifying therapies illustrates that even after approval, new treatment-associate...
Update on disease modifying therapies in MS The successes offered by modern therapies for multiple sclerosis, with a long list of treatments now licenced, has not only brought benefits to patients but also provided important insights into the pathogenesis of the disease. With opti... Compston,Al...
There are five approved, partially effective, parenteral disease-modifying therapies for multiple sclerosis (MS), including three interferon-beta preparations, glatiramer acetate and the antineoplastic agent mitoxantrone. A sixth drug, natalizumab, was withdrawn from the market in 2005 but could return wi...
Background: Little is known about the use of the new oral disease-modifying therapies (DMTs: fingolimod, dimethyl fumarate, teriflunomide) for multiple sclerosis (MS) in clinical practice. We describe their rate of uptake, and their use as compared to the established first-generation (beta-...
Stimulated by the successful introduction of interferon-β as treatment for relapsing-remitting multiple sclerosis (MS) and based on an improved knowle
Further increases in our understanding of the pathogenesis of MS are likely to assist in the identification of new targets for disease-modifying therapies and in the optimisation of current treatments..doi:10.1007/s00415-004-1504-yHans-Peter Hartung...